SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein Mesencephalic Astrocyte Neurotrophic Factor (MANF), today announced that the Berlin-Bremen Stock Exchange (BBSE) has complied with the Company’s demand to cease the unauthorized listing of its common stock, and that as of today its shares are no longer traded on the BBSE. “We are pleased that the Berlin-Bremen Exchange has complied with our demand to end the listing and trading of Amarantus shares,” said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience “I want to thank the law firm of JS Barkats, PLLC in assisting us with the legal actions necessary to obtain a successful conclusion to this case.”
